Pharming news from FierceBiotech
NewsPharming shares spike on positive Rhucin data
Shares of Pharming NV spiked 24 percent on the news that fresh data demonstrated that its lead therapy Rhucin - developed in genetically modified rabbits as a therapy for hereditary angioedema - Read more...
Pharming shares sink after Rhucin gets thumbs down
There's new trouble for Pharming's Rhucin, an experimental treatment for hereditary angioedema. Pharming shares plunged after the company announced that the EMEA's Committee for Medicinal Products Read more...
ALSO NOTED: Acorda shares bounce on new data; Endo CEO hits the exit door; BioSante in protocol deal; and much more...
> Shares of Acorda Therapeutics took a big bounce yesterday when the company announced new data demonstrating that its multiple sclerosis drug Fampridine-SR does not raise heart-related risks Read more...
ALSO NOTED: Shasun sets up NJ plant; Barrier gets a new CEO; Pharming gains grant; and much more...
> India's Shasun Chemicals has set up a processing unit for active pharmaceutical ingredients in New Jersey to supply U.S. customers. Read more...
ALSO NOTED: Savient shares soar on trial results; Pharming handed a rejection on Rhucin;ARCH closes $400M VC fund; and much mor
> It wasn't all bad news on Wall Street. Shares of Savient jumped almost 50 percent after researchers announced that its experimental gout therapy, Puricase, met the main goal of a late-stage Read more...
Pharming raises $99M
Netherlands-based Pharming has raised $99 million (€70 million) through the issue of convertible bonds. The issue was managed by UBS Investment Bank. The company is also finalizing discussions for Read more...
Pharming shares jump on orphan drug designation
Shares of Pharming surged this morning after the Dutch biotech announced that it had won the FDA's orphan drug designation for recombinant human fibrinogen (rhFIB) for the treatment of bleeding in Read more...
Pharming steps up marketing plans on Phase III data
Pharming says that its Phase III trial for Rhucin--a human protein developed to treat acute attacks of hereditary angieoedema--has hit its targets, opening the way to European and U.S. markets as Read more...
Pharming says it's closing in on Rhucin approval
Pharming says that the positive interim results it has received from a study of Rhucin is blazing the way to EMEA approval. The Amsterdam-based developer says it expects EMEA approval in the fourth Read more...
Regulators focusing on transgenic animals
Genetically engineered animals are producing a range of therapies for human use, and The New York Times catches up on the action at companies like Read more...
| Press ReleasesPRESS RELEASE: Pharming prepares to appeal ruling on European marketing authorization application for Rhucin Pharming prepares to appeal ruling on European marketing authorization application for Rhucin LEIDEN, THE NETHERLANDS -- 12/13/07 -- Biotech company Pharming Group NV ("Pharming" or Read more... PRESS RELEASE: Pharming Group Raises 70 Million Euro Pharming Group Raises 70 Million Euro Leiden, The Netherlands, October 19, 2007. Biotech company Pharming Group announced today that it has raised EUR 70 million through the issue of convertible Read more... PRESS RELEASE: Pharming Group Raises 70 Million Euro Pharming Group Raises 70 Million Euro Leiden, The Netherlands, October 19, 2007. Biotech company Pharming Group N.V. announced today that it has raised EUR 70 million through the issue of Read more... PRESS RELEASE: Pharming Presents Positive Phase III Results of Rhucin PHARMING PRESENTS POSITIVE RESULTS FROM EUROPEAN PHASE III TRIAL OF RHUCIN Primary and secondary endpoints of study achieved Leiden, The Netherlands, August 30, 2007. Biotech company Pharming Group Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets